Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
ConditionHidradenitis Suppurativa (HS)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPeking Union Medical College
About this trial
This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.
Eligibility criteria
Qualifiers
age ≥18 years
diagnosis of moderate-to-severe HS with Hurley stage II or III
Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules
inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors
Disqualifiers
active infections (e.g., viral hepatitis, active tuberculosis)
use of other biologics or systemic immunosuppressants within the past three months
severe organ dysfunction (e.g., hepatic or renal failure)
any other conditions that might affect study results
Trial design
Treatments tested in this trial
- Secukinumab
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov